Temozolomide in malignant glioma

References

• LouisDNOhgakiHWiestlerODCaveneeWKWHO classification of tumours of the central nervous systemLyon, FranceIARC2007
   Google Scholar
• EoliMMenghiFBruzzoneMGMethylation of O6-methylguanine DNA methyltransferase and loss of heterozigosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survivalClin Cancer Res2007132606261317473190
   PubMed Web of Science ®Google Scholar
• AbreyLELouisDNPaleologosNSurvey of treatment recommendations for anaplastic oligodendrogliomaNeurooncol20079314318
   Google Scholar
• CairncrossGSeiferheldWShawEPhase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402J Clin Oncol2006242707271416782910
   PubMed Web of Science ®Google Scholar
• HanischUKKettenmannHMicroglia: active sensor and versatile effector cells in normal and pathologic brainNat Neurosci2007101387139717965659
   PubMed Web of Science ®Google Scholar
• CarapanceaMAlexandruOFeteaAGrowth factor receptors signaling in glioblastoma cells: therapeutic implicationsJ Neurooncol20099213714719043776
   PubMed Web of Science ®Google Scholar
• GuhaADashnerKBlackPMWagnerJAStilesCDExpression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInt J Cancer1995601681737829210
   PubMed Web of Science ®Google Scholar
• HermansonMFunaKHartmanMPlateletderived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loopsCancer Res199252321332191317261
   PubMed Web of Science ®Google Scholar
• JainRKdi TomasoEDudaDGAngiogenesis in brain tumorNat Rev Neurosci2007861062217643088
   PubMed Web of Science ®Google Scholar
• PelloskiCBallmanKFurthAEpidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaJ Clin Oncol2007252288229417538175
   PubMed Web of Science ®Google Scholar
• PlateKHBreierGWeichHARisauWVascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivoNature19923598458481279432
   PubMed Web of Science ®Google Scholar
• WongAJBignerSHBignerDDIncreased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplificationProc Natl Acad Sci U S A198784689969033477813
   PubMed Web of Science ®Google Scholar
• GladsonCLChereshDAGlioblastoma expression of vitronectin and the avh3 integrin. Adhesion mechanism for transformed glial cellsJ Clin Invest199188192419321721625
   PubMed Web of Science ®Google Scholar
• MaherEABrennanCWenPYMarked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entitiesCancer Res200666115021151317114236
   PubMed Web of Science ®Google Scholar
• ParsonsDWJonesSZhangXAn integrated genomic analysis of human glioblastoma multiformeScience20083211807181218772396
   PubMed Web of Science ®Google Scholar
• FriedmanHMcLendonRKerbyTDNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant gliomaJ Clin Oncol199816385138579850030
   PubMed Web of Science ®Google Scholar
• SarkariaJNKitangeGJJamesCDMechanisms of chemoresistance to alkylating agents in malignant gliomaClin Cancer Res2008142900290818483356
   PubMed Web of Science ®Google Scholar
• BeithJCookRRobinsonBLJModulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high grade gliomasProc Am Assoc Cancer Res199716386
   Google Scholar
• FriedmanHSCan O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?Clin Cancer Res200062967296810955771
   PubMed Web of Science ®Google Scholar
• SanaiNBergerMSGlioma extent of resection and its impact on patient outcomeNeurosurgery20086275376618496181
   PubMed Web of Science ®Google Scholar
• StummerWPichlmeierUMeinelTFluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trialLancet Oncol2006739240116648043
   PubMed Web of Science ®Google Scholar
• BremHPiantadosiSBurgerPCPlacebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment GroupLancet1995345100810127723496
   PubMed Web of Science ®Google Scholar
• GuyotatJSignorelliFFrappazDIs reoperation for recurrence of glioblastoma justified?Oncol Rep2000789990410854567
   PubMed Web of Science ®Google Scholar
• HauPBaumgartUPfeiferKBockASalvage therapy in patients with glioblastoma: is there any benefitCancer2003982678268614669289
   PubMed Web of Science ®Google Scholar
• PatelMSiddiquiFJinJYSalvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survivalJ Neurooncol20099218519119066727
   PubMed Web of Science ®Google Scholar
• WestphalMHiltDCBorteyEA phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomaNeurooncol200357988
   PubMed Web of Science ®Google Scholar
• WolffJEBerrakSKoontz WebbSENitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patientsJ Neurooncol200888576318253699
   PubMed Web of Science ®Google Scholar
• ChenTCSuSFryDLiebesLCombination therapy with irinotecan and protein kinase C inhibitors in malignant gliomaCancer2003972363237312712458
   PubMed Web of Science ®Google Scholar
• BrandesAAErmaniMTurazziSProcarbazine and high-dose tamoxifen as a second- line regimen in recurrent high-grade gliomas: a phase ii studyJ Clin Oncol19991764565010080610
   PubMed Web of Science ®Google Scholar
• van den BentMJCarpentierAFBrandesAAAdjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer phase III trialJ Clin Oncol2006242715272216782911
   PubMed Web of Science ®Google Scholar
• WalkerMDGreenSBByarDPRandomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgeryN Engl J Med1980303132313297001230
   PubMed Web of Science ®Google Scholar
• BiascoGPantaleoMACasadeiSTreatment of brain metastases of malignant melanoma with temozolomideN Engl J Med200134562162211529230
   PubMed Web of Science ®Google Scholar
• BradaMJudsonIBealePPhase I dose-excalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignanciesBr J Cancer1999811022103010576660
   PubMed Web of Science ®Google Scholar
• O′ReillySMNewlandsESGlaserMGTemozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumorsEur J Cancer199329940942
   Web of Science ®Google Scholar
• NewlandsESStevensMFWedgeSRTemozolomide. A review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treat Rev19972335619189180
   PubMed Web of Science ®Google Scholar
• GersonSLClinical relevance of MGMT in the treatment of cancerJ Clin Oncol2002202388239911981013
   PubMed Web of Science ®Google Scholar
• PazMFYaya-TurRRojas-MarcosICpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomasClin Cancer Res2004104933493815297393
   PubMed Web of Science ®Google Scholar
• YungWKAlbrightREOlsonJA phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer20008358859310944597
   PubMed Web of Science ®Google Scholar
• YungWKPradosMDYaya-TurRMulticenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, Temodal Brain Tumor GroupJ Clin Oncol1999172762277110561351
   PubMed Web of Science ®Google Scholar
• KimSHParkTSLeeSTTherapy-related myelodysplasia/acute myeloid leucemia after treatment with temozolomide in a patient with glioblastoma multiformeAnn Clin Lab Sci20093939239819880768
   PubMed Web of Science ®Google Scholar
• BradaMHoang-XuanKRamplingRMulticenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseAnn Oncol20011225926611300335
   PubMed Web of Science ®Google Scholar
• FranceschiEOmuroAMLassmanABSalvage temozolomide for prior temozolomide respondersCancer20051042473247616270316
   PubMed Web of Science ®Google Scholar
• HappoldCRothPWickWACNU-based chemotherapy for recurrent glioma in the temozolomide eraJ Neurooncol200992454818987781
   PubMed Web of Science ®Google Scholar
• JauchTHauPBogdahnURe-challenge with temozolomide (TMZ) at recurrence in high-grade gliomasProc ASCO20072583s
   Google Scholar
• KappelleACPostmaTJTaphoornMJBPCV chemotherapy for recurrent glioblastoma multiformeNeurology20015611812011148250
   PubMed Web of Science ®Google Scholar
• KongDSLeeJIKimWSA pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastomaOncol Rep2006161117112117016602
   PubMed Web of Science ®Google Scholar
• TriebelsVHTaphoornMJBrandesAASalvage PCV chemotherapy for temozolomide-resistant oligodendrogliomasNeurology20046390490615365146
   PubMed Web of Science ®Google Scholar
• HegiMELiuLHermanJCorrelation of O6-Methylguanine Methyltransferase MGMT promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityJ Clin Oncol2008264189419918757334
   PubMed Web of Science ®Google Scholar
• TolcherAWGersonSLDenisLMarked inactivation of O6-alkylguanine-DNA-alkyltansferase activity with protracted temozolomide schedulesBr J Cancer2003881004101112671695
   PubMed Web of Science ®Google Scholar
• WickWSteinbachJPKukerWMOne week on/one week off: a novel active regimen for temozolomide for recurrent glioblastomaNeurol20046221132115
   PubMed Web of Science ®Google Scholar
• WickAFelsbergJSteinbachJPEfficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent gliomaJ Clin Oncol2007253357336117664483
   PubMed Web of Science ®Google Scholar
• BrandesAATosoniACavalloGTemozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia (GICNO)Br J Cancer2006951155116017024124
   PubMed Web of Science ®Google Scholar
• van RijnJHeimansJJvan den BergJSurvival of human glioma cells treated with various combination of temozolomide and x-raysInt J Radiat Oncol Biol Phys20004777978410837964
   PubMed Web of Science ®Google Scholar
• WedgeSRPorteousJKGlaserMGIn vitro evaluation of temozolomide combined with X-irradiationAnticancer Drugs1997892979147618
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEvan den BentMJEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials GroupChanging paradigms – an update on the multidisciplinary management of malignant gliomaOncologist20061116518016476837
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med200535298799615758009
   PubMed Web of Science ®Google Scholar
• StuppRHegiMMasonWEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol20091045946619269895
   PubMed Web of Science ®Google Scholar
• HegiMDiserensA-CGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med2005352997100315758010
   PubMed Web of Science ®Google Scholar
• ClarkeJLIwamotoFMSulJRandomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed GlioblastomaJ Clin Oncol2009273861386719506159
   PubMed Web of Science ®Google Scholar
• BrandesAAFranceschiETosoniATemozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation statusCancer20091153512351819514084
   PubMed Web of Science ®Google Scholar
• ChamberlainMCChalmersLMA pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastomaJ Neurooncol20078220720917019532
   PubMed Web of Science ®Google Scholar
• IwamotoFMCoeperARReinerASGlioblastoma in the elderly: The Memorial Sloan-Kettering Cancer Center experience (1997–2007)Cancer20091153758376619484785
   PubMed Web of Science ®Google Scholar
• MinnitiGDe SanelisVMuniRHypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastomaJ Neurooncol2009919510018758912
   PubMed Web of Science ®Google Scholar
• HauPKochDHundsbergerTSafety and feasibility of long-term temozolomide treatment in patients with high grade gliomaNeurology20076868869017325277
   PubMed Web of Science ®Google Scholar
• GlasMHappoldCRiegerJLong-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomideJ Clin Oncol2009271257126119188676
   PubMed Web of Science ®Google Scholar
• KoronesDNBenita-WeissMCoyleTEPhase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant gliomaCancer2003971963196812673724
   PubMed Web of Science ®Google Scholar
• McGirtMJThanKDWeingartJDGliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiformeJ Neurosurg200911058358819046047
   PubMed Web of Science ®Google Scholar
• PradosMDYungWKAFineHAPhase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyNeurooncol200463337
   Google Scholar
• RaizerJJMalkinMGKleberMPhase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapyNeurooncol20046247252
   Google Scholar
• SilvaniAEoliMSalmaggiAPhase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patientsJ Neurooncol20046620320815015788
   PubMed Web of Science ®Google Scholar
• NicholasMKLukasRVJafriNFEpidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomasClin Cancer Res2006127261727017189397
   PubMed Web of Science ®Google Scholar
• PradosMChangSButowskiCPhase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaJ Clin Oncol20092757958419075262
   PubMed Web of Science ®Google Scholar
• PradosMDLambornKRChangSPhase I study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant gliomaNeurooncol200686778
   Google Scholar
• LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys2008711372138018355978
   PubMed Web of Science ®Google Scholar
• GuptaVSuYSWangWEnhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericinNeurosurg Focus2006204E2016709026
   PubMedGoogle Scholar
• SpenceAMPetersonRAScharnhorstJDPhase II study of concurrent continous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomasJ Neurooncol200470919515527114
   PubMed Web of Science ®Google Scholar